JP2010526801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526801A5 JP2010526801A5 JP2010507013A JP2010507013A JP2010526801A5 JP 2010526801 A5 JP2010526801 A5 JP 2010526801A5 JP 2010507013 A JP2010507013 A JP 2010507013A JP 2010507013 A JP2010507013 A JP 2010507013A JP 2010526801 A5 JP2010526801 A5 JP 2010526801A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- solvate
- pharmaceutically acceptable
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LWJGMYMNSNVCEM-UHFFFAOYSA-N 1-(4-fluorobenzoyl)-3-[(6-methoxynaphthalen-2-yl)oxymethyl]azetidine-3-carboxylic acid Chemical compound C1=CC2=CC(OC)=CC=C2C=C1OCC(C1)(C(O)=O)CN1C(=O)C1=CC=C(F)C=C1 LWJGMYMNSNVCEM-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- -1 pyridinylphenyl group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 5
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 4
- 208000000450 Pelvic Pain Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 201000010260 leiomyoma Diseases 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 208000005641 Adenomyosis Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000013872 defecation Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000009274 endometriosis of uterus Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 208000007106 menorrhagia Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- REAGPRQUVILCCU-UHFFFAOYSA-N 1-(4-fluorophenoxy)carbonyl-3-[(6-methoxynaphthalen-2-yl)oxymethyl]azetidine-3-carboxylic acid Chemical compound C1=CC2=CC(OC)=CC=C2C=C1OCC(C1)(C(O)=O)CN1C(=O)OC1=CC=C(F)C=C1 REAGPRQUVILCCU-UHFFFAOYSA-N 0.000 claims 1
- XYEMEUZXCFSFRV-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)phenoxy]methyl]-1-(4,4-difluorocyclohexanecarbonyl)azetidine-3-carboxylic acid Chemical compound C1N(C(=O)C2CCC(F)(F)CC2)CC1(C(=O)O)COC(C=C1)=CC=C1C1=CC=C(Cl)C=C1 XYEMEUZXCFSFRV-UHFFFAOYSA-N 0.000 claims 1
- 208000004483 Dyspareunia Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 125000006267 biphenyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 0 **C(N1CC(*)(CO[Al])C1)=O Chemical compound **C(N1CC(*)(CO[Al])C1)=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91708107P | 2007-05-10 | 2007-05-10 | |
| US1303007P | 2007-12-12 | 2007-12-12 | |
| PCT/IB2008/001070 WO2008139287A1 (en) | 2007-05-10 | 2008-04-28 | Azetidine derivatives and their use as prostaglandin e2 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010526801A JP2010526801A (ja) | 2010-08-05 |
| JP2010526801A5 true JP2010526801A5 (enExample) | 2010-09-24 |
Family
ID=39739736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507013A Withdrawn JP2010526801A (ja) | 2007-05-10 | 2008-04-28 | プロスタグランジンｅ２拮抗薬としてのアゼチジン誘導体およびその使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20080280877A1 (enExample) |
| EP (1) | EP2155666A1 (enExample) |
| JP (1) | JP2010526801A (enExample) |
| KR (1) | KR20100009582A (enExample) |
| CN (1) | CN101679235A (enExample) |
| AP (1) | AP2009005047A0 (enExample) |
| AR (1) | AR066524A1 (enExample) |
| AU (1) | AU2008249744A1 (enExample) |
| BR (1) | BRPI0811444A2 (enExample) |
| CA (1) | CA2686517A1 (enExample) |
| CL (1) | CL2008001305A1 (enExample) |
| CO (1) | CO6260066A2 (enExample) |
| CR (1) | CR11101A (enExample) |
| DO (1) | DOP2009000256A (enExample) |
| EA (1) | EA200901381A1 (enExample) |
| EC (1) | ECSP099727A (enExample) |
| GT (1) | GT200900293A (enExample) |
| IL (1) | IL201874A0 (enExample) |
| MA (1) | MA31366B1 (enExample) |
| MX (1) | MX2009011998A (enExample) |
| PA (1) | PA8779601A1 (enExample) |
| PE (1) | PE20090282A1 (enExample) |
| SV (1) | SV2009003407A (enExample) |
| TN (1) | TN2009000470A1 (enExample) |
| TW (1) | TW200904409A (enExample) |
| UY (1) | UY31070A1 (enExample) |
| WO (1) | WO2008139287A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2222665A1 (en) * | 2007-11-15 | 2010-09-01 | Pfizer Limited | Azetidines as ep2 antagonists |
| MX2011004903A (es) | 2008-11-10 | 2011-05-30 | Pfizer Ltd | Pirrolidinas. |
| US20100256385A1 (en) * | 2009-04-02 | 2010-10-07 | Allergan, Inc. | Prostaglandin e receptor antagonists |
| DE102009049662A1 (de) | 2009-10-13 | 2011-04-14 | Bayer Schering Pharma Aktiengesellschaft | 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten |
| TWI589576B (zh) | 2011-07-15 | 2017-07-01 | 諾華公司 | 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法 |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| EP3237401B1 (en) | 2014-12-22 | 2019-03-06 | Pfizer Inc | Antagonists of prostaglandin ep3 receptor |
| CN110041269A (zh) * | 2019-05-16 | 2019-07-23 | 海门瑞一医药科技有限公司 | 一种2-氯-5-羟基嘧啶的制备方法 |
| CN115052478A (zh) * | 2019-11-21 | 2022-09-13 | 犹他大学研究基金会 | Trpv4受体配体 |
| WO2022272060A1 (en) | 2021-06-24 | 2022-12-29 | Reservoir Neuroscience, Inc. | Ep2 antagonist compounds |
| JP2024524981A (ja) * | 2021-06-24 | 2024-07-09 | レザボア ニューロサイエンス，インコーポレイテッド | Ｅｐ２アンタゴニスト化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8300860D0 (en) * | 1983-01-13 | 1983-02-16 | Shell Int Research | Azetidine compounds |
| GB8415614D0 (en) * | 1984-06-19 | 1984-07-25 | Shell Int Research | Azetidine derivatives |
| GB8509746D0 (en) * | 1985-04-16 | 1985-05-22 | Shell Int Research | Preparing azetidine derivatives |
| AR037364A1 (es) | 2001-11-16 | 2004-11-03 | Schering Corp | Azetidinil diaminas utiles como ligandos del receptor de nociceptina orl-1 |
| CN103524392B (zh) * | 2005-10-07 | 2018-06-01 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶 |
| US8383660B2 (en) * | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
-
2008
- 2008-04-28 MX MX2009011998A patent/MX2009011998A/es not_active Application Discontinuation
- 2008-04-28 AU AU2008249744A patent/AU2008249744A1/en not_active Abandoned
- 2008-04-28 KR KR1020097025684A patent/KR20100009582A/ko not_active Ceased
- 2008-04-28 CA CA002686517A patent/CA2686517A1/en not_active Abandoned
- 2008-04-28 AP AP2009005047A patent/AP2009005047A0/en unknown
- 2008-04-28 JP JP2010507013A patent/JP2010526801A/ja not_active Withdrawn
- 2008-04-28 CN CN200880019555A patent/CN101679235A/zh active Pending
- 2008-04-28 EP EP08737574A patent/EP2155666A1/en not_active Withdrawn
- 2008-04-28 EA EA200901381A patent/EA200901381A1/ru unknown
- 2008-04-28 WO PCT/IB2008/001070 patent/WO2008139287A1/en not_active Ceased
- 2008-04-28 BR BRPI0811444-7A2A patent/BRPI0811444A2/pt not_active IP Right Cessation
- 2008-05-05 US US12/115,070 patent/US20080280877A1/en not_active Abandoned
- 2008-05-06 CL CL200801305A patent/CL2008001305A1/es unknown
- 2008-05-08 PE PE2008000813A patent/PE20090282A1/es not_active Application Discontinuation
- 2008-05-08 PA PA20088779601A patent/PA8779601A1/es unknown
- 2008-05-08 UY UY31070A patent/UY31070A1/es not_active Application Discontinuation
- 2008-05-09 TW TW097117225A patent/TW200904409A/zh unknown
- 2008-05-09 AR ARP080101988A patent/AR066524A1/es unknown
-
2009
- 2009-11-01 IL IL201874A patent/IL201874A0/en unknown
- 2009-11-05 DO DO2009000256A patent/DOP2009000256A/es unknown
- 2009-11-06 SV SV2009003407A patent/SV2009003407A/es not_active Application Discontinuation
- 2009-11-06 TN TNP2009000470A patent/TN2009000470A1/fr unknown
- 2009-11-09 CR CR11101A patent/CR11101A/es not_active Application Discontinuation
- 2009-11-09 CO CO09126880A patent/CO6260066A2/es not_active Application Discontinuation
- 2009-11-10 GT GT200900293A patent/GT200900293A/es unknown
- 2009-11-10 EC EC2009009727A patent/ECSP099727A/es unknown
- 2009-11-10 MA MA32331A patent/MA31366B1/fr unknown